ROCKVILLE, Md., Feb. 8, 2016 /PRNewswire-USNewswire/ -- The Emmes Corporation today announced that Dr. Paul VanVeldhuisen has been promoted to the newly created position of chief operating officer. Dr. VanVeldhuisen, who started at Emmes as a statistician and epidemiologist, will assume the additional leadership responsibilities while continuing to serve as principal investigator for government and privately funded research projects.
"Emmes has continued to grow in both revenues and reputation," noted Dr. Anne Lindblad, president and chief executive officer. "The creation of a COO position will help us remain centered on our mission and culture, as we expand the infrastructure and a growing global presence."
She added, "Paul is respected both within and outside the company. He provides oversight for our quality assurance department and serves on Emmes' Institutional Review Board. He has been on numerous National Institutes of Health review panels and more recently Patient-Centered Outcomes Research Institute. Paul's vision, leadership, and understanding of our business and culture make him an ideal COO, and I am looking forward to working with him in his new role."
Dr. VanVeldhuisen joined the company in 1993 and was promoted to vice president in 2006. He is responsible for the scientific aspects of various research studies, including study design and analysis, and he oversees day-to-day operations of clinical trial support. Dr. VanVeldhuisen has contributed to research in important public health areas, including ophthalmology, drug abuse, organ transplantation and infectious disease. He also received the company's Public Health Impact Award in 2013 for his team's research on the safety of cesarean sections.
"I'm looking forward to my new role," noted Dr. VanVeldhuisen. "What has stayed consistent during my 22 years here is our commitment to provide critical services that address important issues in public health. We're involved in long-term studies on childhood cancer, clinical trials of HIV vaccines, vaccine trials associated with a pandemic threat, studies aimed at preventing and treating vision loss, and research in real-world settings examining prevention and treatment of substance use. These are the kinds of challenges that inspire our staff to do their best. It's the dedicated employees committed to Emmes' mission that make this a remarkable place to work."
Dr. VanVeldhuisen holds a Ph.D. in epidemiology from The George Washington University, an M.S. in biostatistics from the University of Washington, and a B.S. in mathematics from Calvin College. He lives in Brookeville, Maryland, with his family.
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit our new and improved website at www.emmes.com.
SOURCE The Emmes Corporation